Cerebrolysin is not a single peptide. It is a standardised biological preparation produced by the controlled enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids in aqueous solution. It is manufactured by EVER Neuro Pharma in Austria, and one millilitre of the solution for injection contains 215.2 mg of Cerebrolysin concentrate. Because the product is defined by its manufacturing process rather than by a sequence, no independent laboratory can reproduce it exactly, and no single active moiety within the mixture has been identified.
That distinction shapes everything else on this page. A synthetic single-sequence peptide can be made to the same specification anywhere in the world and tested against itself; a proteolytic tissue extract cannot. Every trial of Cerebrolysin is therefore a trial of one manufacturer's product, and the mechanistic literature describes what that mixture does in a model system rather than what a defined molecule does at a defined receptor.
Cerebrolysin holds national marketing authorisations in a number of countries — Austria and several central and eastern European states, Russia, China and much of Asia — for indications spanning acute ischaemic stroke, dementia and traumatic brain injury. It has never been approved by the FDA and is not legally marketed in the United States. It is given intravenously or intramuscularly; oral administration is not a route the product is formulated for, as the peptide fraction would be digested before reaching the circulation.
The evidence base is unusual in both its size and its polarisation. Dozens of randomised trials have been run across three decades, most of them sponsored by the manufacturer, and several report clear benefit on multidimensional outcome scales. Independent Cochrane reviews of the same field have repeatedly concluded that Cerebrolysin probably makes little or no difference to death or dependency in acute ischaemic stroke, and have identified a signal of increased non-fatal serious adverse events. Both bodies of work are described below, because the disagreement between them is the most important fact about this compound.
A mixture of low-molecular-weight neuropeptide fragments. The registered medicine is supplied as a ready-made sterile solution; the research material charted here is a 60 mg lyophilised vial reconstituted with bacteriostatic water before measurement.
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Week 1 | 20 mg | 100 units1 mL |
| Week 2 | 24 mg | 120 units1.2 mL |
| Week 3 | 28 mg | 140 units1.4 mL |
| Weeks 4–12 | 32 mg | 160 units1.6 mL |
FrequencyOnce daily, subcutaneous, in week one; twice daily from week two onward, with the day's amount split between a morning and an evening injection at separate sites — 12 mg and 12 mg in week two, 14 mg and 14 mg in week three, 16 mg and 16 mg from week four.
For review — a circulated research protocol, not established human dosing. This is the 60 mg lyophilised vial schedule published by peptidedosages.com, which titrates a subcutaneous amount upward week by week. The registered medicine is a ready-made solution given by diluted intravenous infusion in a clinic, and its published trial dosing is a different preparation by a different route. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — the once-or-twice-daily subcutaneous cadence comes from the circulated 60 mg vial protocol, not from a published trial. The trial programmes behind Cerebrolysin used daily intravenous infusion.
The 60 mg vial reconstituted with 3 mL of bacteriostatic water comes to 20 mg/mL, on which one syringe unit is 0.01 mL and carries 200 mcg. The protocol starts at 20 mg a day and adds roughly 4 mg a week as tolerated, reaching 28 to 32 mg by weeks three and four, and runs as an 8 to 12 week course that is sometimes extended to 16. Anything above 100 units — 1 mL — is divided between a morning and an evening injection at separate sites, which is why the cadence stated under the chart changes from week two onward. Published human dosing for the registered product is a different thing entirely: a course of 10 to 30 mL of ready-made solution a day by diluted intravenous infusion for 10 to 21 consecutive days, given in a clinic. Cerebrolysin is a registered medicine in several countries and is not approved in the United States.
Measurement note. At the water volumes above the largest amount in the chart comes to 160 units, which is more than the 1 mL a 100-unit U-100 syringe holds, so at this concentration the upper steps could not be drawn in a single fill at all.
What this evidence establishes. Two preparations sit behind this page. The registered medicine is a ready-made sterile solution of peptide fragments measured in millilitres and given by infusion, and it is what the published trials used. The 60 mg lyophilised vial charted above is research material, reconstituted and measured on a U-100 syringe scale, and its week-by-week schedule is a circulated protocol rather than a trial finding.
Sources: CASTA trial programme · CARS trial programme · peptidedosages.com — Cerebrolysin 60 mg vial dosage protocol
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
The mechanisms attributed to Cerebrolysin come almost entirely from cell-culture and animal work on the mixture as a whole. They describe proposed activity, not established clinical mechanism in humans.
Preclinical work describes effects resembling those of endogenous neurotrophic factors such as BDNF, GDNF and NGF. Cerebrolysin does not contain these proteins; the resemblance is functional in model systems, not structural.
The preparation is a blend of low-molecular-weight peptides and free amino acids. No single constituent has been isolated and shown to account for the observed activity.
Animal models of ischaemia report reduced glutamate-mediated excitotoxic injury. Whether this occurs at clinically used exposures in people has not been demonstrated.
Rodent studies report changes in markers of synaptic plasticity and neurogenesis after injury. These are laboratory endpoints, not the clinical outcomes the trials measured.
Administered by intravenous infusion or intramuscular injection. Volumes above 10 mL are given as slow infusion rather than bolus in the manufacturer's instructions.
Composition figures differ between published descriptions, and batch and manufacturer variability is acknowledged. This is a structural obstacle to independent mechanistic confirmation.
Key pharmacological distinction: for most compounds profiled on this site, the mechanism is a specific interaction between a defined sequence and a defined target — ipamorelin at the ghrelin receptor, tesamorelin at the GHRH receptor. Cerebrolysin has no such description. Its proposed mechanism is the aggregate behaviour of an undefined mixture, which is why mechanistic claims about it cannot be tested the way single-molecule claims can.
Three limitations run through the whole literature. First, sponsorship: the large majority of positive trials were funded or conducted by the manufacturer, and independent replication is scarce. Second, endpoints: several of the positive results rest on multidimensional ensembles of many rating scales analysed together, which is a legitimate statistical approach but is not interchangeable with a hard clinical outcome such as death or dependency — in the TBI literature, scale-based scores have moved where all-cause mortality and length of stay did not. Third, the product itself: because Cerebrolysin is a batch-defined biological mixture rather than a defined molecule, a failure to replicate can always be attributed to the preparation, which makes the disagreement structurally difficult to resolve.
None of the trials described here support use of Cerebrolysin outside a supervised clinical setting, and none establish a dose or schedule for cognitive enhancement, anti-ageing or any other use in healthy people. No trial has enrolled healthy participants.
Contraindications below are drawn from the manufacturer's product information; wording differs slightly between national labels, and the applicable version is the one authorised in the relevant country.
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| Hypersensitivity to the preparation | CONTRAINDICATED | Listed as a contraindication in the manufacturer's product information. The preparation is derived from porcine brain tissue, so hypersensitivity to porcine material is directly relevant. |
| Epilepsy / status epilepticus | CONTRAINDICATED | Named as a contraindication on the manufacturer's label. Some national labels specify status epilepticus and advise caution in generalised epilepsy because of a possible increase in seizure frequency. |
| Severe renal impairment | CONTRAINDICATED | Listed as a contraindication. Pharmacokinetic data in renal impairment are lacking and clinical experience in renal failure is limited. |
| Non-fatal serious adverse events | SIGNAL IDENTIFIED | The 2023 Cochrane review reported more non-fatal serious adverse events with Cerebrolysin than placebo in acute ischaemic stroke (RR 2.39, 95% CI 1.10 to 5.23; three trials, 1,335 participants; moderate-certainty evidence). |
| Animal-tissue origin | MODERATE | A porcine-derived biological carries inherent hypersensitivity risk. The manufacturer directs that facilities for treating an allergic reaction be available during administration. |
| Rapid intravenous administration | MODERATE | Vasodilatory effects such as flushing and dizziness are associated with fast injection. Larger volumes are directed to be given as a slow infusion rather than a bolus. |
| Pregnancy and lactation | INSUFFICIENT DATA | Data are insufficient to establish safety, and the label treats these as precautions. |
| Unsupervised or non-clinical use | NOT SUPPORTED | Every trial administered the product under medical supervision in a hospital setting, in stroke, dementia or TBI populations. There is no evidence base for self-administration or for use in healthy people. |
FDA: Cerebrolysin is not FDA-approved for any indication and is not legally marketed in the United States. Orphan drug designation has been granted for investigation in a neurodegenerative indication, which is a research incentive and not a finding of safety or efficacy.
Outside the United States: the product holds national marketing authorisations in a number of countries, including Austria and several central and eastern European states, Russia and much of Asia, with indications that vary by jurisdiction across stroke, dementia and traumatic brain injury. Approval in one country is not evidence of efficacy accepted elsewhere; the same trial data has been assessed differently by different regulators.
Key distinction: Cerebrolysin is not an under-studied compound — it is a heavily studied one whose independent and sponsored literatures disagree. That is a different situation from the preclinical-only compounds elsewhere on this site, and it calls for a different kind of caution. The relevant question is not whether trials exist but whose trials they are, what endpoints they used, and why three decades of independent review have not converged on a recommendation.
Test your understanding of what Cerebrolysin is, what the trials measured, and why independent reviews disagree with the sponsored literature.
This profile is for educational and research purposes only. It is not medical advice, and nothing on it is a protocol, a recommendation, or an instruction for use in a person or an animal.
Athena Peptides Education does not prescribe, sell, or recommend any compound. Compounds discussed here are for laboratory research only and are not for human consumption. Always consult a qualified physician before making any decision about your health.